Houston-based Milkify will pitch their freeze-drying breast milk concept on Shark Tank this Friday. Photo courtesy of Milkify

A Houston startup is competing in the "Super Bowl of Business," as founder Pedro Silva calls it, and you can watch the action later this week.

Milkify will appear on ABC’s “Shark Tank” this Friday, April 7. Silva, co-founder and CEO, created Milkify along with his wife, Berkley Luck, PhD, in 2019. Today, Luck is a mom, COO, and a molecular biologist, but she had the idea for the company back in grad school. A coworker was struggling with pumping breast milk “lugging the pump back to work,” as Luck puts it.

Luck was studying probiotics at the time and was using a freeze-dryer in her work. The problem inspired her to create a process of freeze-drying breast milk that is now patent pending. The trademarked process is centered around SafeDry, special freeze-drying pouches.

“The breast milk never makes contact with our equipment,” Luck explains. The powdered milk is transferred directly from the bag in which it’s freeze-dried to the final packaging under sterile conditions. The result is not only shelf-stable, but keeps for at least three years, exponentially longer than frozen milk.

Silva admits that when Luck first pitched Milkify to him, he thought it was a crazy idea. “But Berkley is way smarter than I am. There must be something to it,” he realized. At the time, he was working in energy private equity. But he vowed that if they could find a viable path to making Milkify a business, he would join Luck full-time.

Early in the company’s life, the couple purchased a blue van that said “We will freeze-dry your breast milk,” recalls Silva. This grassroots marketing introduced them to a neighbor whose baby refused to drink her frozen milk. “He spat it out, he hated the taste,” Silva says. The pair freeze-dried her milk for the baby and their neighbor soon sent a video of the little one chugging six ounces of her rehydrated milk.

“That was the lightbulb moment,” says Silva. “How often do you get to work on something really meaningful?”

Since its founding, Milkify has freeze-dried and powdered more than half a million ounces of breast milk, all carefully preserved and packaged individually. Last October, Milkify opened what Luck claims is, “The only GMP-certified processing facility in the world right now specifically designed for freeze-drying breast milk.”

The 6,400-square-foot Houston space is a vast improvement from the previous 200-square-foot facility. That was thanks to raising $1.2 million in funds, which has also allowed them to build a larger staff.

“Our entire workforce at this point other than Pedro is moms,” says Luck. Including the couple, they are a team of 10, and just hired two additional members. They are currently looking to hire, says Silva, with roles including both operations and logistics associates. Experience, he says, is less important than conscientiousness and a good attitude, as they will train their new hires in-house.

And Milkify is about to receive more attention than ever with its appearance on “Shark Tank.” “Getting on a national stage to share our story was the main motivation for it,” says Luck. That translates to both education about the potential for freeze-drying breast milk, and about Milkify’s unique model.

“We started this business as a labor of love. It wasn’t just a financial reason,” says Silva. “This can actually help a lot of people. This is a way to spread the word.” And in the process, help countless moms and babies.

Berkley Luck and Pedro Silva — the wife and husband team behind Milkify — appear on Shark Tank this Friday. Photo courtesy of Milkify

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.